Lazard Said to Poach Rothschild's Jensen to Lead Nordic Push
Updated on
Save
Lazard Inc. has hired one of Rothschild & Co. 's most seasoned investment bankers in the Nordics to bolster its client network in the region, according to people familiar with the matter.
Jesper Jensen, who spent the past decade at Rothschild, is set to join Lazard in late October as a managing director based in Copenhagen, said the people, who asked not to be identified as the information is private.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
Yahoo
44 minutes ago
- Yahoo
Synovus CEO says ballpark name change coming, just not sure when that will be
COLUMBUS, Ga. () — It was announced late last week that Columbus Synovus will be merging with Pinnacle Financial Partners. One of the questions that has been repeatedly asked is what will happen to the name of the ballpark with the Double-A Columbus Clingstones play? WRBL News 3 asked Synovus Chairman, President and CEO Kevin Blair that question during an exclusive interview on Friday. He said the merger process was at the very beginning, and it was too early for a definitive answer. 'Obviously, if we are rebranding Pinnacle, we want to make that park Pinnacle Park. It is some alliteration to it,' Blair said. The merger with Nashville-based Pinnacle is expected to be finalized in the first quarter of 2026. At that time, Synovus will take the name Pinnacle Bank. Blair, who will be the CEO and president of the merged companies, says the name rebranding process could take 12-14 months, which means it will likely be completed in 2027. Synovus purchased the naming rights for what was formerly Golden Park from the Clingstones ownership group, Diamond Baseball Holdings, last year. The city of Columbus invested $50 million to overhaul the park for the Atlanta Braves affiliate. This is the Clingstones first season in Synovus Park. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
Nvidia's (NVDA) Data Center Boom Continues — Analyst Lifts Price Target to $192
NVIDIA Corporation (NASDAQ:NVDA) is one of the . On July 23, Rothschild & Co Redburn's Timm Schulze‑Melander raised his price target on the stock to $192 from $173, maintaining a 'Buy' outlook. The firm said that earnings visibility is improving. Moreover, AI models' performance has improved roughly 5% per quarter since May 2023. This has, in turn, incited 'huge spending' on Nvidia data‑center compute. 'Nvidia is back to playing offense and recent sovereign investment deals improve earnings visibility. We raise our FY26-28 estimates between 1% and 5% and raise our price target to $192 from $178.' NVIDIA Corporation (NASDAQ:NVDA) specializes in AI-driven solutions, providing high-performance GPUs and platforms that power data centers, autonomous vehicles, robotics, and cloud services. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
